Core Viewpoint - Jingtai Holdings (02228) experienced a significant stock increase of over 6%, reaching HKD 11.4 with a trading volume of HKD 41.9461 million, following the announcement of a strategic collaboration with Eli Lilly valued at up to USD 345 million [1] Group 1: Strategic Collaboration - Jingtai Technology's wholly-owned subsidiary Ailux has entered into a multi-target strategic cooperation and platform licensing agreement with Eli Lilly, with a total agreement value potentially reaching USD 345 million, including several million dollars in upfront payments and milestone payments [1] - This collaboration aims to leverage Ailux's proprietary platform to accelerate the discovery and development of bispecific antibodies across multiple therapeutic areas, while also utilizing its AI antibody research platform to enhance internal pipeline research [1] Group 2: Previous Collaborations - This agreement follows a previous collaboration in 2023, where Jingtai Technology and Eli Lilly signed a USD 250 million partnership focused on AI small molecule drugs, indicating a continued partnership between the two companies [1] Group 3: Ailux Development - Ailux, which has been a key focus for Jingtai Technology since 2021, has rapidly developed and commercialized its large molecule drug research platform over the past two years [1] - The platform employs a hybrid research model that combines AI-driven antibody drug design and engineering, effectively addressing the challenges of high costs and long timelines in drug discovery, enabling pharmaceutical companies to explore diverse targeting mechanisms and differentiated drug development pathways [1] - Ailux is expected to advance AI-designed next-generation antibody drugs into later clinical stages, aiming for more impactful major commercial collaborations in the future [1]

Major Events - Wangshan Wangshui-B (02630) has set its share price at HKD 33.37, with the Hong Kong public offering receiving a subscription rate of 6,238.42 times [1] - WeRide-W (00800) achieved a subscription rate of 73.44 times for its Hong Kong public offering, raising approximately HKD 2.264 billion from the global offering [1] - Pony.ai-W (02026) had a subscription rate of 15.88 times for its Hong Kong public offering, with a share price set at HKD 139 [1] - Joyson Electronics (00699) saw a subscription rate of 147.67 times for its Hong Kong public offering, with an expected listing date of November 6 [1] - Standard Chartered Group (02888) plans to issue USD 1 billion in fixed-rate reset perpetual subordinated or convertible securities [1] - Crystal Tech Holdings (02228) subsidiary AILUX announced a strategic partnership with Eli Lilly to enhance AI-driven bispecific antibody development [1] - Giant Star Legend (06683) signed a sales contract exceeding HKD 100 million for quadruped robots, accelerating the integration of "IP + Robotics + AI" [1] - HAPO-B (02142) entered into an evaluation and licensing agreement with UMOJA BIOPHARMA [1] Financial Data - Hong Kong Exchanges and Clearing (00388) reported a profit attributable to shareholders of HKD 13.419 billion for the first three quarters, a year-on-year increase of 45%, with both revenue and profit reaching record highs [1] - Fubo Group (03738) experienced a total revenue growth of approximately 27% in the third quarter [1] - Goodbaby International (01086) reported a revenue of approximately HKD 6.42 billion for the first three quarters, reflecting a year-on-year decline of 1.1% [1]

Core Insights - Crystal Tech Holdings (02228.HK) announced a strategic partnership with Eli Lilly to accelerate the discovery and development of bispecific antibodies for various diseases [1] - The partnership grants Eli Lilly access to Ailux's AI-driven bispecific antibody engineering platform, which integrates advanced structural modeling, generative design, and developmental analysis technologies [1] - The collaboration includes upfront and milestone payments totaling several tens of millions of USD, with potential total milestone payments reaching up to $345 million [1] Company Overview - Ailux Shanghai, a wholly-owned subsidiary of Crystal Tech Holdings, focuses on developing advanced biotherapies using AI-driven solutions [2] - The company has assembled a global team of over 100 members and actively collaborates with leading biopharmaceutical companies to translate cutting-edge scientific achievements into transformative drugs [2] - Crystal Tech Holdings was founded in 2015 by three MIT physicists and operates as an innovative R&D platform leveraging quantum physics, AI, and robotics [2] Financial Performance - In the first half of the year, Crystal Tech Holdings reported a revenue increase of 404% year-on-year, reaching 517 million RMB, with an adjusted net profit of 141 million RMB [3] - Historical revenue figures for Crystal Tech show 62.8 million RMB in 2021, 133 million RMB in 2022, and 80 million RMB in 2023, while net losses were 2.137 billion RMB, 1.439 billion RMB, and 1.906 billion RMB respectively during the same period [3] - The company has raised over 5 billion RMB through eight rounds of financing prior to its IPO, with notable investors including Tencent, Sequoia China, and SoftBank Vision Fund [3] Market Performance - Crystal Tech Holdings has a current market capitalization of 46.26 billion HKD, with a year-to-date increase of nearly 80% [4]

Group 1 - Crystal Holdings (02228) announced a strategic collaboration between its wholly-owned subsidiary Ailux Shanghai and Eli Lilly to accelerate the discovery and development of bispecific antibodies for various diseases [1] - The collaboration allows Eli Lilly to utilize Ailux's AI-driven bispecific antibody engineering platform, which integrates advanced structural modeling, generative design, and developmental analysis to create innovative and effective antibody molecules [1] - The collaboration includes upfront and milestone payments totaling several tens of millions of dollars, with a potential total value of up to $345 million, including development, regulatory, and commercial milestone payments [1] Group 2 - Ailux Shanghai is an indirect wholly-owned subsidiary of Ailux Holdings Limited, which is a wholly-owned subsidiary of Crystal Holdings [2] - Ailux serves as Crystal's exclusive biopharmaceutical innovation platform, developing advanced biotherapies through AI-driven solutions [2] - Ailux combines proprietary computational models with cutting-edge wet lab capabilities to tackle traditionally undruggable targets and design biologics with innovative drug potential, supported by a global team of over 100 people [2]

Group 1 - Ailux, a subsidiary of Crystal Tech Holdings, has entered into a strategic collaboration with Eli Lilly to accelerate the discovery and development of bispecific antibodies for various diseases [1] - The collaboration allows Eli Lilly to utilize Ailux's AI-driven bispecific antibody engineering platform, which integrates advanced structural modeling, generative design, and developmental analysis [1] - The total potential value of the collaboration, including development, regulatory, and commercial milestone payments, could reach up to $345 million [1] Group 2 - Ailux is an exclusive biopharmaceutical innovation platform of Crystal Tech Holdings, utilizing AI-driven solutions to develop advanced biotherapies [2] - Ailux combines proprietary computational models with cutting-edge wet lab capabilities to tackle traditionally undruggable targets and design biologics with innovative drug potential [2] - Ailux has a global team of over 100 people working with leading biopharmaceutical companies to translate advanced science into transformative medicines [2]

Core Insights - Ailux Shanghai, a subsidiary of Crystal Tech Holdings, has entered into a strategic collaboration with Eli Lilly to accelerate the discovery and development of bispecific antibodies for various diseases [1] Collaboration Details - The partnership allows Eli Lilly to utilize Ailux's AI-driven bispecific antibody engineering platform, which integrates advanced structural modeling, generative design, and developmental analysis [1] - Eli Lilly can nominate targets for bispecific antibody design and gain access to Ailux's patented platform for internal use [1] - The collaboration includes upfront payments and milestone payments totaling several tens of millions of dollars, with a potential total value of up to $345 million, including development, regulatory, and commercial milestone payments [1] Company Background - Crystal Tech was founded in 2015 by three physicists from MIT and operates as an innovative R&D platform driven by quantum physics, artificial intelligence, and robotics [1] - The company provides digital and intelligent R&D solutions for various industries, including pharmaceuticals, materials science, agricultural technology, energy, new chemicals, and cosmetics [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或 因倚賴該等內容而引致的任何損失承擔任何責任。 XtalPi Holdings Limited （ 於 開 曼 群 島 註 冊 成 立 之 有 限 公 司 ） （股份代號：2228） 晶泰控股有限公司 自願性公告 晶泰子公司AILUX宣佈與禮來戰略合作 賦能（AI驅動）雙特異性抗體開發 Ailux上海為Ailux Holdings Limited（「Ailux Holdings」，連同其子公司統稱「Ailux」） 的間接全資子公司。Ailux Holdings則為晶泰的全資子公司。Ailux為晶泰的專屬 生物製藥創新平台，以AI驅動解決方案開發先進的生物療法。作為晶泰的專屬 生物製藥平台，Ailux將專有計算模型與尖端濕實驗能力相結合，攻克傳統不 可成藥靶點，設計具有創新藥潛力的生物藥分子。Ailux的全球團隊超過100人， 與頂尖生物製藥公司聯手，致力於將最先進的科學轉化為變革性藥物。 關於晶泰 晶泰於2015年由三名麻省理工學院物理學家創立，是一 ...

本月底法定/註冊股本總額： USD 1,000,000 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年10月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 晶泰控股有限公司 ("本公司"） 呈交日期: 2025年11月5日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02228 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | 100,000,000,000 | USD | | 0.00001 | USD | | 1,000,000 | | 增加 / 減少 (-) | | | 0 | | | USD | | 0 | | 本月底結存 | | 100,000,000,000 | USD | | 0.00001 | ...

Core Insights - The Hang Seng Index fell by 0.79% on November 4, with southbound trading totaling HKD 1000.97 billion, including HKD 549.64 billion in buying and HKD 451.32 billion in selling, resulting in a net inflow of HKD 98.32 billion [1] Trading Activity - The most actively traded stock by southbound funds was Alibaba-W, with a total trading amount of HKD 74.27 billion, followed by SMIC and Xiaomi Group-W with HKD 42.55 billion and HKD 36.09 billion respectively [1] - In terms of net buying, China National Offshore Oil Corporation (CNOOC) led with a net inflow of HKD 10.46 billion, while Xiaomi Group-W and China Mobile had net inflows of HKD 10.02 billion and HKD 7.53 billion respectively [1] - The stocks with the highest net selling were Alibaba-W, with a net outflow of HKD 8.68 billion, followed by Sunny Optical Technology and SMIC with net outflows of HKD 3.25 billion and HKD 2.34 billion respectively [1] Continuous Net Buying/Selling - Among the stocks, CNOOC and Xiaomi Group-W were notable for continuous net buying, with Xiaomi Group-W having a total net inflow of HKD 29.15 billion over five days, and CNOOC with HKD 26.49 billion over four days [2] - Conversely, SMIC, Alibaba-W, and Tencent Holdings experienced continuous net selling, with total net outflows of HKD 23.26 billion, HKD 21.89 billion, and HKD 21.63 billion respectively [2]

Market Overview - On November 4, the Hang Seng Index fell by 0.79%, closing at 25,952.40 points, while southbound funds through the Stock Connect recorded a net purchase of HKD 9.832 billion [1] Trading Activity - The total trading volume for the Stock Connect on November 4 was HKD 100.097 billion, with a net purchase of HKD 9.832 billion. Specifically, the Shanghai Stock Connect had a trading volume of HKD 61.300 billion and a net purchase of HKD 5.202 billion, while the Shenzhen Stock Connect had a trading volume of HKD 38.796 billion and a net purchase of HKD 4.631 billion [1] Active Stocks - In the Shanghai Stock Connect, Alibaba-W had the highest trading volume at HKD 44.666 billion, followed by SMIC and Xiaomi Group-W with trading volumes of HKD 26.778 billion and HKD 22.200 billion, respectively. In terms of net buying, Xiaomi Group-W led with a net purchase of HKD 0.908 billion, despite its closing price dropping by 2.91%. Conversely, Alibaba-W experienced the highest net selling at HKD 0.586 billion, with a closing price decline of 2.57% [1] Shenzhen Stock Connect Highlights - In the Shenzhen Stock Connect, Alibaba-W also topped the trading volume with HKD 29.600 billion, followed by Tencent Holdings and SMIC with trading volumes of HKD 17.460 billion and HKD 15.760 billion, respectively. Tencent Holdings saw the highest net purchase of HKD 0.379 billion, with a slight closing price increase of 0.16%. The stock with the highest net selling was Sunny Optical Technology, which had a net selling amount of HKD 0.325 billion, closing down by 4.59% [2]